What's happening
Scribe Therapeutics priced an upsized initial public offering of 8,580,000 shares at $15.00 per share on July 23, 2026, generating gross proceeds of $128.7 million before deductions. The offering was upsized from its original terms, and underwriters were granted a 30-day option to purchase up to an additional 1,287,000 shares. The company's shares began trading on the Nasdaq under the ticker SCTX on July 24, 2026, with the offering scheduled to close on July 27, 2026.
Alongside the public offering, Scribe completed a concurrent private placement of 500,000 shares at $15.00 per share to pharmaceutical giant Sanofi, also expected to close July 27. Prior to the IPO, the company had raised $150 million in total private financing, including a $100 million Series B round in 2021. As of the end of Q1 2026, Scribe held a cash position of $49.7 million; the company projects that post-IPO proceeds will extend its operational runway into the first half of 2029. Post-IPO, Andreessen Horowitz holds nearly 17% of the company, while Eli Lilly holds approximately 6.5%.
Why it matters for markets
The $128.7 million raise — upsized from its original terms — arrives at a moment when the broader CRISPR therapeutics sector is navigating the transition from rare disease applications toward larger patient populations. Scribe's IPO filing articulates this ambition directly: "While current genetic medicines are largely limited to rare disorders, we are engineering our technologies for use in common diseases affecting millions." The company's lead target, atherosclerotic cardiovascular disease (ASCVD) via PCSK9 gene editing, addresses a condition that affects a substantially larger patient pool than the rare genetic disorders that have historically anchored gene-editing pipelines. The company has also secured up to $25.7 million in grant funding from the California Institute for Regenerative Medicine (CIRM) for preclinical programs, providing non-dilutive capital alongside the IPO proceeds.
Scribe's proprietary XE platform features engineered CasX nucleases, which the company positions as offering improved precision and delivery relative to Cas9-based systems, with smaller enzyme size enabling better viral vector packaging. The company's filing frames its cardiovascular thesis in structural terms: "We believe that fixing the chronic care model in ASCVD will come not from adding another pill to the regimen or slightly modifying existing modalities, but rather from a genetic medicine solution that can deliver nature's genetic blueprint for better cardiovascular health to all patients." The participation of Sanofi in the concurrent private placement and the existing stake held by Eli Lilly — two major pharmaceutical players with established cardiovascular franchises — underscores the strategic interest that large-cap pharma has placed in Scribe's platform ahead of clinical readouts.
Sectors and assets to watch
The primary sector to monitor is CRISPR-based gene editing in cardiometabolic disease, where Scribe Therapeutics (SCTX) now represents a newly public clinical-stage entrant. The company's lead program, STX-1150, targeting PCSK9 for elevated LDL cholesterol and ASCVD, places it in a competitive landscape that includes both established gene-editing firms and large-cap pharmaceutical companies with existing PCSK9 franchises. Sanofi, which participated in Scribe's concurrent private placement, markets the PCSK9 inhibitor evolocumab's competitor Praluent and has broader cardiovascular interests, making its investment in Scribe a notable signal of strategic positioning within the genetic medicine space.
The involvement of Eli Lilly — holding a 6.5% post-IPO stake — and Andreessen Horowitz at nearly 17% reflects a shareholder base that spans both life sciences industry incumbents and technology-focused venture capital. Broader gene-editing peers and in vivo delivery platform companies operating in the cardiometabolic space may also draw investor attention as Scribe's Phase 1 data timeline in Australia approaches its anticipated first-half 2027 readout window.
What to watch next
The most immediate milestone to monitor is the close of both the IPO and the Sanofi concurrent private placement, both scheduled for July 27, 2026, as well as any exercise of the underwriters' 30-day overallotment option for up to 1,287,000 additional shares. Beyond the offering mechanics, the critical clinical catalyst is preliminary Phase 1 data from the STX-1150 study currently underway in Australia, expected in the first half of 2027; those results will represent the first in-human evidence for Scribe's XE platform in a cardiometabolic indication. Investors and analysts will also be tracking how the company deploys its post-IPO capital against its stated runway into the first half of 2029, and whether any of its CIRM-funded preclinical programs advance toward investigational new drug filings during that period.